HSBC Holdings’s Protagonist Therapeutics PTGX Stock Holding History

HSBC Holdings’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.2M	Buy	25,952 +24,045	+1,261%	+$2.51M	﹤0.01%	1392
2026 Q1	$201K	Buy	+1,907	New	+$169K	﹤0.01%	2615
2025 Q3	–	Sell	-4,340	Closed	-$242K	–	3053
2025 Q2	$242K	Sell	4,340 -4,118	-49%	-$198K	﹤0.01%	2581
2025 Q1	$405K	Buy	8,458 +330	+4%	+$13.8K	﹤0.01%	2188
2024 Q4	$313K	Buy	8,128 +2,259	+38%	+$98.5K	﹤0.01%	2476
2024 Q3	$262K	Sell	5,869 -1,660	-22%	-$67.1K	﹤0.01%	2438
2024 Q2	$257K	Sell	7,529 -105,358	-93%	-$3.09M	﹤0.01%	2395
2024 Q1	$3.27M	Sell	112,887 -6,447	-5%	-$175K	﹤0.01%	1272
2023 Q4	$2.74M	Sell	119,334 -434,971	-78%	-$7.61M	﹤0.01%	1365
2023 Q3	$9.17M	Sell	554,305 -6,150	-1%	-$119K	0.01%	857
2023 Q2	$15.7M	Buy	+560,455	New	+$14M	0.02%	685

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

HSBC Holdings's PTGX Position: Q2 2026 in Review

HSBC Holdings increased its Protagonist Therapeutics (PTGX) stake by 1,261% in Q2 2026, buying an estimated $2.51M and bringing the position to 25,952 shares worth $3.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1392.

HSBC Holdings first reported a position in PTGX in Q2 2023 and has held it in 11 quarters since. The position peaked at $15.7M in Q2 2023. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

HSBC Holdings held 25,952 shares of Protagonist Therapeutics worth $3.2M as of Q2 2026.
HSBC Holdings bought 24,045 Protagonist Therapeutics shares in Q2 2026, an estimated $2.51M.
Protagonist Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #1392 holding.
HSBC Holdings first reported a position in Protagonist Therapeutics in Q2 2023 and has held it in 11 quarters since.
HSBC Holdings's Protagonist Therapeutics position peaked at $15.7M in Q2 2023.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.